Australia markets closed

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.12000.0000 (0.00%)
At close: 04:00PM EDT
4.1900 +0.07 (+1.70%)
After hours: 07:15PM EDT

MacroGenics, Inc.

9704 Medical Center Drive
Rockville, MD 20850
United States
301 251 5172

Full-time employees339

Key executives

NameTitlePayExercisedYear born
Dr. Scott Koenig M.D., Ph.D.President, CEO & Director1.2MN/A1952
Mr. James KarrelsSenior VP, CFO & Corporate Secretary693.31kN/A1967
Dr. Stephen L. Eck M.D., Ph.D.Senior VP of Clinical Development & Chief Medical Officer766.85kN/A1955
Mr. Eric Blasius RisserChief Operating Officer651.36kN/A1973
Dr. Thomas M. Spitznagel Ph.D.Senior Vice President of Technical Operations550.97k204.5k1967
Dr. Ezio Bonvini M.D.Senior VP of Research & Chief Scientific Officer612.21k264.03k1954
Mr. Jeffrey Stuart PetersSenior VP, General Counsel & Corporate Compliance OfficerN/AN/A1971
Ms. Lynn CilinskiVP, Controller & TreasurerN/AN/A1958
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Corporate governance

MacroGenics, Inc.’s ISS governance QualityScore as of 1 June 2024 is 5. The pillar scores are Audit: 3; Board: 3; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.